Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA) -- Ignore unavailable to you. Want to Upgrade?

To: Ken S. who wrote (1796)	5/4/2004 11:51:38 PM
From: Lizzie Tudor	Respond to of 1870

wow

To: Ken S. who wrote (1796)	5/5/2004 3:59:35 PM
From: Art Bechhoefer	Respond to of 1870

Ken, that data does NOT refute my comment on toxicity for the following reason. My understanding of antisense technology is that an antisense drug may inhibit an enzyme whose presence helps the body fight decarbazine, making that substance less effective. When administered with Genasense, the decarbazine drug may act as if it had been taken in a larger dosage without Genasense. So the effect of Genasense is to heighten the effects of decarbazine--good and bad--and to suggest that a better result might be obtained using a lower dosage of decarbazine in combination with Genasense. We may learn more about this at the conference call later this afternoon. Art